Retrospective review of experience with sarcomatoid renal cell carcinoma: Multimodality treatment remains an unmet goal
Autor: | Sandeep Kondisetty, Gowrinath Kondisetty, Pallavi Vijay Borkar, Appu Thomas |
---|---|
Rok vydání: | 2019 |
Předmět: |
medicine.medical_specialty
sunitinib Urology medicine.medical_treatment 030232 urology & nephrology lcsh:RC870-923 metastatic renal cell carcinoma Metastasis 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma medicine Sarcomatoid Renal Cell Carcinoma sarcomatoid renal cell carcinoma Chemotherapy business.industry Sunitinib Retrospective cohort study lcsh:Diseases of the genitourinary system. Urology medicine.disease Nephrectomy Adjuvant chemotherapy Log-rank test 030220 oncology & carcinogenesis Original Article business medicine.drug |
Zdroj: | Urology Annals Urology Annals, Vol 11, Iss 4, Pp 385-388 (2019) |
ISSN: | 0974-7796 |
DOI: | 10.4103/ua.ua_106_18 |
Popis: | Background: Sarcomatoid change in Renal cell carcinoma(RCC) is associated with adverse outcomes with median survival of 6 months. Settings and Design: This is a retrospective study of patients diagnosed of sarcomatoid RCC(sRCC) between 2007 and 2013 which were followed up till 2017. Methods and Material: Patients (n=22) were grouped based on whether they received additional chemotherapy following nephrectomy. Two groups were followed up until 2017 and overall survival was record. Overall survival curves were estimated by Kaplan-Meier method and compared using Log Rank (Mantel-Cox) test between two groups. Statistical analysis used: Kaplan-Meier method and Log Rank (Mantel-Cox) test. Results: The patients who had chemotherapy had 13.4 cm of mean tumour size with a mean survival of 20.4 ± 8.3 months. The patients who did not undergo chemotherapy had mean tumour size of 11.7 cm with a mean survival of 21 ± 5.9 months. There was no much statistical difference between the two groups in OS with P value = 0.99. Conclusion: The current adjuvant chemotherapy used in sRCC patients who develop metastasis gives no survival advantage. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |